You just read:

Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer's Disease At 18-Months

News provided by

Eisai Inc.

Jun 05, 2018, 01:55 ET